ethosuximide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1087 77-67-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethosuximide
  • ethosuxide
  • etosuximid
  • 3-Methyl-3-ethylsuccinimide
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
  • Molecular weight: 141.17
  • Formula: C7H11NO2
  • CLOGP: 0.40
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.17
  • ALOGS: -0.15
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 39.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 25 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 118.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,SIK2,STK33,TEK 24
kinase-selectivity-class BRAF,GRK2,PDK1,STK33 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Nov. 2, 1960 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple-drug resistance 277.02 46.81 59 2290 7717 90618381
Seizure 248.76 46.81 106 2243 152523 90473575
Drug ineffective 145.76 46.81 177 2172 1384121 89241977
Status epilepticus 141.41 46.81 41 2308 18833 90607265
Intellectual disability 140.67 46.81 25 2324 1261 90624837
Petit mal epilepsy 139.39 46.81 31 2318 4927 90621171
Generalised tonic-clonic seizure 128.22 46.81 44 2305 34859 90591239
Aplastic anaemia 118.18 46.81 33 2316 13236 90612862
Oropharyngeal oedema 80.87 46.81 13 2336 355 90625743
Treatment failure 76.52 46.81 63 2286 303865 90322233
Aggression 72.80 46.81 27 2322 26641 90599457
Myoclonic epilepsy 67.36 46.81 14 2335 1613 90624485
Lupus-like syndrome 60.12 46.81 28 2321 48818 90577280
Suicidal behaviour 59.57 46.81 14 2335 2830 90623268
Atonic seizures 57.84 46.81 11 2338 805 90625293
Macroglossia 50.89 46.81 10 2339 869 90625229
Epilepsy 49 46.81 29 2320 82177 90543921

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 162.54 54.27 168 1776 630029 41989362
Seizure 152.12 54.27 84 1860 120477 42498914
Multiple-drug resistance 142.61 54.27 38 1906 7284 42612107
Developmental delay 124.99 54.27 29 1915 3153 42616238
Petit mal epilepsy 121.03 54.27 29 1915 3621 42615770
Myoclonic epilepsy 108.49 54.27 23 1921 1651 42617740
Status epilepticus 102.41 54.27 35 1909 15543 42603848
Somnolence 99.74 54.27 68 1876 141037 42478354
Ataxia 97.36 54.27 34 1910 16091 42603300
Tonic convulsion 91.72 54.27 20 1924 1639 42617752
Generalised tonic-clonic seizure 74.43 54.27 32 1912 26347 42593044
Treatment failure 60.93 54.27 37 1907 62587 42556804
Electroencephalogram abnormal 60.43 54.27 16 1928 2976 42616415

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Petit mal epilepsy 325.69 35.76 70 3576 7477 110578176
Multiple-drug resistance 296.78 35.76 72 3574 13163 110572490
Seizure 245.17 35.76 127 3519 221058 110364595
Status epilepticus 217.86 35.76 68 3578 31503 110554150
Drug ineffective 209.17 35.76 251 3395 1520289 109065364
Generalised tonic-clonic seizure 166.79 35.76 64 3582 54616 110531037
Ataxia 143.37 35.76 49 3597 30059 110555594
Intellectual disability 129.84 35.76 26 3620 1953 110583700
Treatment failure 123.58 35.76 89 3557 277145 110308508
Myoclonic epilepsy 110.58 35.76 24 3622 2667 110582986
Somnolence 109.16 35.76 85 3561 297364 110288289
Developmental delay 100.62 35.76 20 3626 1445 110584208
Aplastic anaemia 94.38 35.76 34 3612 24274 110561379
Drug resistance 84.82 35.76 40 3606 56334 110529319
Tonic convulsion 80.59 35.76 19 3627 3055 110582598
Oropharyngeal oedema 74.70 35.76 13 3633 452 110585201
Epilepsy 68.30 35.76 42 3604 100167 110485486
Drug interaction 63.39 35.76 80 3566 500103 110085550
Suicidal behaviour 53.33 35.76 14 3632 3483 110582170
Benzodiazepine drug level decreased 52.71 35.76 7 3639 35 110585618
Psychotic disorder 52.56 35.76 28 3618 50909 110534744
Atonic seizures 51.39 35.76 11 3635 1143 110584510
Off label use 49.00 35.76 133 3513 1500052 109085601
Cerebellar atrophy 48.87 35.76 11 3635 1442 110584211
Social avoidant behaviour 47.39 35.76 14 3632 5355 110580298
Lupus-like syndrome 46.58 35.76 24 3622 40768 110544885
Aggression 45.97 35.76 27 3619 59183 110526470
Macroglossia 43.42 35.76 10 3636 1451 110584202
Behaviour disorder 43.15 35.76 15 3631 9632 110576021
Oliguria 40.08 35.76 17 3629 18640 110567013
SJS-TEN overlap 35.91 35.76 9 3637 1865 110583788
Hepatic adenoma 35.86 35.76 7 3639 460 110585193

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AD01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
ATC N03AD51 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:194338 T-type calcium channel blocker
FDA EPC N0000175753 Anti-epileptic Agent

Related Drugs by ATC class:

N03AD Succinimide derivatives 2 drugs
methsuximidephensuximide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Absence seizure indication 79631006
Suicidal thoughts contraindication 6471006
Mood swings contraindication 18963009
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel BLOCKER WOMBAT-PK CHEMBL

External reference:

IDSource
4018631 VUID
N0000146944 NUI
D00539 KEGG_DRUG
4018631 VANDF
C0015043 UMLSCUI
CHEBI:4887 CHEBI
CHEMBL696 ChEMBL_ID
DB00593 DRUGBANK_ID
D005013 MESH_DESCRIPTOR_UI
3291 PUBCHEM_CID
1077 INN_ID
7182 IUPHAR_LIGAND_ID
5SEH9X1D1D UNII
4135 RXNORM
4199 MMSL
4701 MMSL
d00227 MMSL
001631 NDDF
387244008 SNOMEDCT_US
44790008 SNOMEDCT_US
5SEH9X1D1D INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0237 CAPSULE 250 mg ORAL NDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-708 CAPSULE 250 mg ORAL ANDA 18 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-711 CAPSULE 250 mg ORAL ANDA 18 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2350 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 62135-064 SOLUTION 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 62135-790 CAPSULE 250 mg ORAL ANDA 13 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8005 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 68382-443 CAPSULE 250 1 ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 68999-064 SOLUTION 250 mg ORAL ANDA 12 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69387-108 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69452-152 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections